Cargando…
Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE – COALITION VIII randomised clinical trial
BACKGROUND: COVID-19 progression is associated with an increased risk of arterial and venous thrombosis. Randomised trials have demonstrated that anticoagulants reduce the risk of thromboembolism in hospitalised patients with COVID-19, but a benefit of routine anticoagulation has not been demonstrat...
Ejemplares similares
-
Justificativa e Desenho do Ensaio Clínico Randomizado COVID-19 Outpatient Prevention Evaluation (COPE - Coalition V): Hidroxicloroquina vs. Placebo em Pacientes Não Hospitalizados
por: de Oliveira, Haliton Alves, et al.
Publicado: (2022) -
Rivaroxabana em Pacientes Ambulatoriais com COVID-19 Leve ou Moderada: Fundamentação e Desenho do Estudo CARE (CARE – Coalition COVID-19 Brazil VIII)
por: Oliveira, Gustavo B. F., et al.
Publicado: (2023) -
Hidroxicloroquina para Pacientes com COVID-19 não Hospitalizados: Uma Revisão Sistemática e Metanálise de Ensaios Clínicos Randomizados
por: Lucchetta, Rosa, et al.
Publicado: (2023) -
Clinical Equivalence between Generic Versus Branded Antibiotics: Systematic Review and Meta-Analysis
por: Cotia, André, et al.
Publicado: (2023) -
Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE – Coalition V): A double-blind, multicentre, randomised, controlled trial
por: Avezum, Álvaro, et al.
Publicado: (2022)